Our data suggests that a potential therapeutic outcome of combined BRCA2 downregulation and olaparib treatment would be to prevent tumor spread and growth at secondary sites in the peritoneal cavity following surgical resection of primary tumors. Here, BRCA2 is linked to neoplasm.